How U.S. insurance companies are blocking COVID-19 mutation surveillance

COVID-19 testing.
(Image credit: Mario Tama/Getty Images)

The United States is not at the top of its game when it comes to coronavirus sequencing, which makes tracking COVID-19 mutations a challenge, Bloomberg reports. That's a real concern as the Delta variant and other potentially concerning variants spread around the U.S. and the world.

Part of the reason the U.S. lags behind other countries when it comes to mutation surveillance is because sequencing positive tests isn't mandatory, Jade Fulce, a spokeswoman for the Centers for Disease Control and Prevention, told Bloomberg. Therefore, the agency doesn't receive sufficient data from specific states or jurisdictions, forcing scientists to rely on "geographically broad regions," instead.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us
Tim O'Donnell

Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.